Medical News

RSS

At hearing, Kucinich bashes insurance companies

An afternoon hearing today seeks to better understand how private health insurance works. Capitol News Connection reports: "This afternoon Rep. Dennis Kucinich (D-OH) leads Day Two of a House oversight inquiry. The Ohio Democrat wants to know how private health insurance companies decide whom to cover and which claims to pay. And how those decisions translate to profit ratios" (Johnson, 9/17).

17 Sep 2009

Lantheus commences Phase 1 study evaluating novel LMI1195 heart failure imaging agent

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the initiation of a Phase 1 clinical study to assess the safety, dosimetry and tolerability of LMI1195, a novel F-18 small molecule tracer for imaging cardiac neuronal function, in healthy subjects, undergoing positron emission tomography (PET) imaging.

17 Sep 2009

Interim data from GORE PROPATEN Vascular Graft studies presented at the 2009 vascular meeting

W. L. Gore & Associates (Gore) today announced that several physicians recently presented interim data from ongoing GORE PROPATEN® Vascular Graft studies to clinical audiences at the 2009 annual vascular meeting. The conference, the premier event hosted by the Society for Vascular Surgery (SVS), was held in mid-June in Denver, Colorado. One physician reported primary patency rates as high as 100 percent for below-knee bypasses.

17 Sep 2009

China SFDA approves clinical trial of China Aoxing's abuse resistant opioid drug

China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China Aoxing"), a China-based pharmaceutical company specializing in research, development, manufacturing and distribution of narcotic and pain-management products, today announced that its Clinical Trial Application ("CTA") for Tilidine/Naloxone Capsules, an opioid drug with abuse resistance property, was officially approved by the China State Food and Drug Administration ("SFDA").

17 Sep 2009

Quidel's QuickVue Influenza A+B test receives special 510(k) clearance for H1N1 reactivity update

Quidel Corporation (NASDAQ: QDEL), a global leader in point-of-care (POC) rapid diagnostic tests, received Special 510(k) clearance for an update to the Company's QuickVue® Influenza A+B test package insert to include reactivity with culture isolates of the 2009 H1N1 Influenza A virus.

17 Sep 2009

Enzo expands its capability to perform simultaneous live-cell imaging of nuclear components

Enzo Life Sciences, a division of Enzo Biochem, Inc. (NYSE:ENZ), has added a novel new system to its CELLestial™ line of live cell analysis products, providing expanded capability to simultaneously image both the nucleus and the nucleolus in living cells, the Company announced today. Called the Total Nuclear-ID™ Green/Red Nucleolar/Nuclear Detection Kit, the new addition has been specifically optimized for demanding live cell microscopy applications.

17 Sep 2009

CCPHA research reveals the serious health risks of drinking soda

While health officials have long suspected the link between obesity and soda consumption, research released today provides the first scientific evidence of the potent role soda and other sugar-sweetened beverages play in fueling California’s expanding girth.

17 Sep 2009

InterMune and National Jewish Health to collaborate in the research of idiopathic pulmonary fibrosis

InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).

17 Sep 2009

Fourth-quarter and fiscal year end 2009 results announced by Pioneer Behavioral Health

PHC, Inc., d/b/a Pioneer Behavioral Health (NYSE Amex: PHC), a leading provider of inpatient and outpatient behavioral health services, reported financial results for the company's fourth fiscal quarter and year ended June 30, 2009. The results exclude the operations of the company`s research division, Pivotal Research Centers, Inc. ("Pivotal"), which was sold during the 2009 third fiscal quarter and was classified as a discontinued operation.

17 Sep 2009

4D Medical Systems launches the 4D PhotoStation System in the U.S.

4D Medical Systems, Inc. announced the U.S. launch of the 4D PhotoStation™ System today. The 4D PhotoStation System eliminates the costs and complexities of digital photography in the medical practice while increasing photo-imaging revenue opportunities. Photographic documentation is well known for melanoma, cosmetic procedure before and afters and documenting effects of procedures.

17 Sep 2009

GENova and PacificWave sign engagement agreement

GENova Biotherapeutics Inc. ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it has signed an engagement agreement with PacificWave Partners Limited ("PacWave") for raising a minimum of USD5m to the company as well as actively look for potential buy-out and/or acquisition targets.

17 Sep 2009

Second-quarter fiscal 2009 results announced by Gentium

Gentium S.p.A. (NASDAQ: GENT) today reported financial results for the second quarter ended June 30, 2009.

17 Sep 2009

Protein aggregation is linked to many conformational diseases

Researchers at the Department of Biochemistry and Molecular Biology of Universitat Autònoma de Barcelona (UAB) have revealed the process by which proteins with a tendency to cause conformational diseases such as amyotrophic lateral sclerosis, familial amyloidotic polyneuropathy, familial amyloidotic cardiomyopathy, etc. finally end up causing them.

17 Sep 2009

A not-for-profit mission from Wellcome Trust and Merck to develop affordable vaccines for low-income countries

The Wellcome Trust and Merck & Co., Inc. today announced the creation of the MSD Wellcome Trust Hilleman Laboratories (www.hillemanlaboratories.in), the first of its kind research and development joint venture with a not-for-profit mission to focus on developing affordable vaccines to prevent diseases that commonly affect low-income countries.

17 Sep 2009

Nutrisystem and House Foods to promote Nutrisystem J Diet in Japan

As part of a plan to expand its brand, Nutrisystem Inc., is announcing a licensing agreement with House Foods International, to market Nutrisystem J Diet in Japan.

17 Sep 2009

Nimotuzumab drug approved for Mexican distribution

YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that nimotuzumab has been approved for marketing in Mexico.

17 Sep 2009

Essilor announces first-ever eco-friendly eyewear

Back to school is an important time for families and eyesight, as many schools require eye exams and teachers notice vision needs through classroom activities. With the start of a new school year, it's also a chance for families to kick start a new routine to support the environment and establish every day green habits.

17 Sep 2009

Study reveals that YAP can be used for the diagnosis of gastric carcinoma

A research team led by Professor Yan Xin, from The Fourth Laboratory of Cancer Institute in China measured the expression of YAP and survivin in normal gastric mucosa, precancerous lesions and gastric carcinoma using an immunohistochemical method to analyze the significance and correlations of the 2 factors with gastric carcinogenesis.

17 Sep 2009

CEO Cancer Gold Standard accreditation for Meridian Health

Meridian Health has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

17 Sep 2009

Intarcia's ITCA 650 phase 2 study in type 2 diabetes begins patient enrollment

Intarcia Therapeutics, Inc. today announced the start of enrollment for a phase 2 study comparing its proprietary drug candidate ITCA 650 (DUROS continuous delivery of exenatide) with Byetta, an FDA-approved twice-daily injection form of exenatide.

17 Sep 2009

Medical News

At hearing, Kucinich bashes insurance companies

Lantheus commences Phase 1 study evaluating novel LMI1195 heart failure imaging agent

Interim data from GORE PROPATEN Vascular Graft studies presented at the 2009 vascular meeting

China SFDA approves clinical trial of China Aoxing's abuse resistant opioid drug

Quidel's QuickVue Influenza A+B test receives special 510(k) clearance for H1N1 reactivity update

Enzo expands its capability to perform simultaneous live-cell imaging of nuclear components

CCPHA research reveals the serious health risks of drinking soda

InterMune and National Jewish Health to collaborate in the research of idiopathic pulmonary fibrosis

Fourth-quarter and fiscal year end 2009 results announced by Pioneer Behavioral Health

4D Medical Systems launches the 4D PhotoStation System in the U.S.

GENova and PacificWave sign engagement agreement

Second-quarter fiscal 2009 results announced by Gentium

Protein aggregation is linked to many conformational diseases

A not-for-profit mission from Wellcome Trust and Merck to develop affordable vaccines for low-income countries

Nutrisystem and House Foods to promote Nutrisystem J Diet in Japan

Nimotuzumab drug approved for Mexican distribution

Essilor announces first-ever eco-friendly eyewear

Study reveals that YAP can be used for the diagnosis of gastric carcinoma

CEO Cancer Gold Standard accreditation for Meridian Health

Intarcia's ITCA 650 phase 2 study in type 2 diabetes begins patient enrollment

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News